Patients describe Casgevy gene-editing treatment as a cure, says Vertex CEO Reshma Kewalramani

Reshma Kewalramani, CEO of Vertex Pharmaceuticals, and CNBC’s Angelica Peebles join 'Power Lunch' to discuss the latest FDA gene-editing treatment approval, drug pricing, and more.

[@williamhowell9811]

Please post the rest of the interview! Some of the most important points have been left out.

[@indiancitizen3013]

People who have this disease are actually poor 😢 how they can survive 😮

[@brimmo2012]

2.2 million per person for a one time treatment/cure of this drug?? 😮

[@BUY_YOUTUBE_VIEWS_g0g9]

This video is so good; it could be the anthem for a global celebration.

[@williamhowell9811]

Only a part of the interview. Cost of the disease is 4 - 6 million dollars without this treatment

[@mychalharmon1]

So if it costs that much, do poor people just have to go without treatment?

[@pietjan2650]

Elysium

[@ramsita8198]

Good news 😂😂😂😂😂😂😂

[@thetradersam6157]

$2.2mm per person??????, non-sense...

[@mychalharmon1]

The American Oligarchy wins again. $2.2 mil? Are you going to have to be a billionaire to survive cancer?